Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Rheumatoid Arthritis

In brief

The primary objective of this study is to evaluate the efficacy of andecaliximab (GS-5745) versus placebo as an add-on therapy to a tumor necrosis factor (TNF) inhibitor and methotrexate in adults with moderate to severe rheumatoid arthritis (RA).

Key facts

Study ID

NCT02862574

Run by

Gilead Sciences

People needed

15

Starts

2016-12-15

Expected to finish

2017-08-07

Last updated by the study team

2018-06-27

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Stanford University — Palo Alto, California, United States
• Omega Research Consultants, LLC — DeBary, Florida, United States
• G. Timothy Kelly, MD — Las Vegas, Nevada, United States
• Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States
• Albuquerque Center for Rheumatology — Albuquerque, New Mexico, United States
• Altoona Center for Clinical Research — Duncansville, Pennsylvania, United States
• Tekton Research — Austin, Texas, United States
• Accurate Clinical Research — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.